Key result
LV collagen volume fraction >32% is linked to ~103% higher major adverse outcomes in DCM.
Why the study?
Does the extent of left ventricular collagen volume fraction (LV-CVF) assessed by left ventricular endomyocardial biopsy predict outcomes in patients with suspected dilated cardiomyopathy?
Cohort (n=524)
Does the extent of left ventricular collagen volume fraction (LV-CVF) assessed by left ventricular endomyocardial biopsy predict outcomes in patients with suspected dilated cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Left ventricular endomyocardial biopsy is a safe procedure, and the quantification of collagen volume fraction provides independent prognostic value in patients with dilated cardiomyopathy.
Aims The need to perform endomyocardial biopsy (EMB) in patients with non‐ischaemic dilated cardiomyopathies (DCM) is debated. Here we sought to determine the extent of left ventricular collagen volume fraction (LV‐CVF) in DCM patients and to evaluate it as a prognostic marker. Methods and results In this retrospective longitudinal study, we included 524 patients with suspected DCM who underwent left ventricular EMB (LV‐EMB) as a part of their clinical work‐up. LV‐CVF was quantified using automated image processing of high‐resolution scans of LV‐EMB. Deep phenotyping was performed including assessment of late gadolinium enhancement on cardiac magnetic resonance imaging. Endpoints were (i) composite endpoint of heart failure‐related death, sudden cardiac death, aborted sudden cardiac death (appropriate implantable cardioverter‐defibrillator shock, reported sustained ventricular tachycardia, or cardiopulmonary resuscitation), or cardiac transplantation, and (ii) all‐cause mortality. LV‐EMB was associated with 0.76% major and 2.1% minor complications. No death occurred due to EMB. LV‐CVF could be reliably quantified using Bayesian classification. During a median follow‐up of 43.2 months (2084 patient‐years), 48 patients with LV‐CVF >32% and 14 patients with LV‐CVF ≤32% reached the composite endpoint (log‐rank p < 0.0001). A total of 62 patients reached the endpoint all‐cause mortality, from which 38 presented with LV‐CVF >32% and 17 with LV‐CVF ≤32% (log‐rank p = 0.009). In multivariable analyses, LV‐CVF and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) (hazard ratio 2.03, 95% confidence interval 1.32–3.11) were independent predictors of unfavourable outcome. Conclusions Left ventricular EMB is a safe diagnostic procedure. The extent of CVF in LV‐EMB provides prognostic information in patients with DCM in addition to existing measures of left ventricular ejection fraction or NT‐proBNP.
No takes yet. Share an insight, caveat, or question.
Kayvanpour et al. (2025) conducted a cohort in Dilated cardiomyopathy (n=524). Left ventricular collagen volume fraction (LV-CVF) >32% vs. LV-CVF ≤32% was evaluated on Composite of heart failure-related death, sudden cardiac death, aborted sudden cardiac death, or cardiac transplantation (HR 2.03, 95% CI 1.32-3.11, p=<0.0001). Left ventricular collagen volume fraction >32% was associated with a higher risk of the composite adverse outcome in patients with dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: